24,020 results match your criteria Infectious Myositis

Delayed-onset Necrotizing Myositis following COVID-19 Infection.

Eur J Case Rep Intern Med 2021 20;8(4):002461. Epub 2021 Apr 20.

Department of Allergy, Immunology and Rheumatology, Rochester Regional Health, Rochester, NY, USA.

As the numbers of cases of COVID-19 continue to rise, the heterogeneity of its clinical manifestation continues to increase. Here, we describe a case of delayed-onset, biopsy-proven necrotizing myositis following infection with SARS-CoV-2.

Learning Points: SARS-CoV-2 may be associated with late-onset necrotizing myositis, mimicking autoimmune inflammatory myositis. Read More

View Article and Full-Text PDF

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma.

Cureus 2021 Apr 9;13(4):e14387. Epub 2021 Apr 9.

Rheumatology, Wright-Patterson Medical Center, Dayton, USA.

Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. Read More

View Article and Full-Text PDF

Multifocal reactive myositis induced by .

Rheumatol Adv Pract 2021 5;5(2):rkab025. Epub 2021 Apr 5.

Department of Rheumatology, Royal Berkshire Hospital NHS Foundation Trust, Reading.

View Article and Full-Text PDF

Vaccination as a possible trigger for immune-mediated necrotising myopathy.

BMJ Case Rep 2021 May 11;14(5). Epub 2021 May 11.

Laboratory of Neuromuscular Disease, Department of Neurosciences, Centro Universitário FMABC, Santo Andre, Brazil

Immune-mediated necrotising myopathy is a rare autoimmune myopathy characterised by severe progressive muscle weakness, elevated levels of creatine kinase (CK), and necrosis with minimal inflammatory cell infiltration on muscle biopsy. We report a case of a previously healthy 42-year-old woman who presented with progressive muscle weakness 2 weeks after immunisation for yellow fever, tetanus/diphtheria and hepatitis B. Her symptoms started from the lower limbs and progressed to the upper limbs and cervical region associated with dysphagia, making her wheelchair bound. Read More

View Article and Full-Text PDF

Premature live birth in a woman with antisynthetase syndrome following recurrent miscarriages.

BMJ Case Rep 2021 May 11;14(5). Epub 2021 May 11.

Department of Obstetric Medicine, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.

Antisynthetase syndrome (anti-SS) is a rare systemic autoimmune disease characterised by autoantibodies against aminoacyl-tRNA synthetases manifesting as one or more components of the classic triad: interstitial lung disease, arthritis and myositis. While it is well-recognised that autoimmune rheumatological disorders in general can contribute to multiple pregnancy complications, very little is known about how anti-SS itself affects pregnancy outcomes. Described here is the case of a 26-year-old pregnant woman with anti-SS whose pregnancy course was complicated by placental dysfunction and subsequent extremely premature delivery at 24 weeks' gestation. Read More

View Article and Full-Text PDF

Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.

Rheumatology (Oxford) 2021 May 11. Epub 2021 May 11.

Service de Physiologie, Explorations Fonctionnelles Musculaires, CHU de Strasbourg, Strasbourg, France.

Objective: We recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren's syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms of the characteristics of the myositis is currently unknown. Anti-cytosolic 5'-nucleotidase 1 A (cN1A) has recently been proposed as a biomarker for IBM but is also frequent in SS. Read More

View Article and Full-Text PDF

Prognosis and treatment of myositis-associated severe interstitial lung disease: A descriptive study using a nation-wide inpatient database in Japan.

Arthritis Care Res (Hoboken) 2021 May 10. Epub 2021 May 10.

Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.

Objectives: The aim of this study was to determine the prognosis, clinical course, and current management of severe interstitial lung disease (ILD) associated with myositis in Japan.

Methods: We conducted a retrospective descriptive study using a nation-wide database for inpatient care of acute illness in Japan. Among a total of approximately 66 million inpatient admissions, we identified patients with severe ILD associated with polymyositis (PM) or dermatomyositis (DM) which required mechanical ventilation and methylprednisolone pulse therapy (≥1g/day usage of methylprednisolone) from July 2010 to March 2018. Read More

View Article and Full-Text PDF

Red mark syndrome of trout (Oncorhynchus mykiss; Walbaum, 1792): Histopathological scoring and correlation with gross lesions.

J Fish Dis 2021 May 10. Epub 2021 May 10.

Veterinary Pathology Unit, DI4A, University of Udine, Udine, Italy.

Red mark syndrome (RMS) is a skin disorder affecting rainbow trout (Oncorhynchus mykiss). The present work aimed to correlate the gross skin lesions affecting 46 fish sampled from farms surveyed for RMS with their microscopic features, identifying histological parameters that may be suggestive of disease progression. Skin lesions were grossly included in one of three categories (types I, II and III) according to the progressive degree of severity. Read More

View Article and Full-Text PDF

Histopathological features of systemic sclerosis-associated myopathy: A scoping review.

Autoimmun Rev 2021 May 7:102851. Epub 2021 May 7.

Division of Rheumatology, Centre hospitalier de l'Université de Montréal (CHUM), CHUM Research Center, Department of Medicine, Université de Montréal, Montréal, Québec, Canada. Electronic address:

Background: Scleromyositis (SM) is an emerging subset of myositis associated with features of systemic sclerosis (SSc) but it is currently not recognized as a distinct histopathological subset by the European NeuroMuscular Center (ENMC). Our aim was to review studies reporting muscle biopsies from SSc patients with myositis and to identify unique histopathological features of SM.

Methods: A scoping review was conducted and included all studies reporting histopathological findings in SSc patients with myositis searching the following databases: PubMed, MEDLINE, EMBASE, CINAHL and EBM-Reviews. Read More

View Article and Full-Text PDF

Multifocal Post-Traumatic Myositis Ossificans Circumscripta in a Young Male Following a Motor Vehicle Accident: A Review of Imaging and Clinical Presentation.

Cureus 2021 Apr 6;13(4):e14328. Epub 2021 Apr 6.

Internal Medicine, Westside Regional Medical Center, Plantation, USA.

Traumatic myositis ossificans (MO) circumscripta is an uncommon nonhereditary pathophysiological result of muscular trauma that is detected by radiographic imaging three to four weeks following initial trauma. It is responsible for great global morbidity, with symptoms of prolonged pain, diminished flexibility, and stiffness. There is frequently a delay in diagnosis due to the generalized symptoms and varying radiographic presentation. Read More

View Article and Full-Text PDF

Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Front Immunol 2021 22;12:672008. Epub 2021 Apr 22.

Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo-Esquelético (IIRSME), Universidad de Guadalajara, Guadalajara, Mexico.

The idiopathic inflammatory myopathies (IIM) are characterized by muscular weakness, cutaneous manifestations, muscle damage revealed by increase of muscular enzymes, muscle biopsy, electromyography and changes on magnetic resonance imaging. However, the hallmark of these IIM, is the development of myositis specific antibodies (MSA) or myositis associated antibodies (MAA). The theories about their presence in the serum of IIM is not known. Read More

View Article and Full-Text PDF

Association of CD40 Gene Polymorphisms With Systemic Lupus Erythematosus and Rheumatoid Arthritis in a Chinese Han Population.

Front Immunol 2021 22;12:642929. Epub 2021 Apr 22.

Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, Luzhou, China.

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complex autoimmune diseases. CD40 participates in inflammatory response, and promotes fibroblast proliferation, leading to occurrence and progression of SLE, RA. This study explores CD40 gene polymorphisms in SLE and RA patients from a Chinese Han population. Read More

View Article and Full-Text PDF

Myositis with Anti-mitochondrial Antibody Type 2 with Diplopia and Ptosis.

Intern Med 2021 May 7. Epub 2021 May 7.

Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.

Anti-mitochondrial antibody type 2 is a diagnostic marker of primary biliary cirrhosis and complicates myositis. Myositis with anti-mitochondrial antibody type 2 is clinically characterized by slowly progressive limb, cardiac, and respiratory muscle weakness as well as serum creatinine kinase elevations. However, there has been few cases with eye symptoms. Read More

View Article and Full-Text PDF

Rhabdomyolysis Following Recovery from Severe COVID-19: A Case Report.

Am J Case Rep 2021 May 8;22:e931616. Epub 2021 May 8.

Oregon Health & Science University, Portland, OR, USA.

BACKGROUND Rhabdomyolysis occurs when muscle injury leads to the release of muscle cell constituents into circulation, often leading to significant systemic complications. There are many causes of rhabdomyolysis, and the etiology is often multifactorial or unclear. Current data suggest that acute COVID-19 may cause muscle injury that can lead to rhabdomyolysis, particularly in cases of severe illness requiring prolonged hospitalization; however, data on the long-term effects of COVID-19 on the musculoskeletal system are lacking. Read More

View Article and Full-Text PDF

Pheochromocytoma presenting as an authentic small vessel vasculitis and complicated with pulmonary embolism: An original presentation.

Ann Cardiol Angeiol (Paris) 2021 May 4. Epub 2021 May 4.

Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia.

Diagnosis of pheochromocytoma can be simple when classic manifestations are present. It can also be challenging and complicated in some cases because of its wide array of faces and presentations. We present a case of a 30-year-old female patient who came with acute respiratory distress, chest pain, hemoptysis, asthenia, anorexia, weight loss of 20kg, and paresthesia in her lower limbs. Read More

View Article and Full-Text PDF

Comment on: Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America.

Rheumatology (Oxford) 2021 May 7. Epub 2021 May 7.

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Okayama, Japan. Address: 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan.

View Article and Full-Text PDF

Tropical pyomyositis in scrub typhus: a rare association.

BMJ Case Rep 2021 May 6;14(5). Epub 2021 May 6.

Neurology, Institute of Postgraduate Medical Education and Research Bangur Institute of Neurology, Kolkata, India.

Tropical pyomyositis manifests as single or multiple abscesses inside skeletal muscles and it has a higher prevalence in immunocompromised patients. Scrub typhus, a zoonotic disease is caused by and the clinical manifestations range from simple febrile illness to organ threatening complications. Here, we present a rare case of an immunocompetent young man diagnosed as tropical pyomyositis in association with scrub typhus. Read More

View Article and Full-Text PDF

ANCA-associated vasculitis and severe proximal muscle weakness.

Proc (Bayl Univ Med Cent) 2021 Jan 14;34(3):384-386. Epub 2021 Jan 14.

Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida.

ANCA-associated vasculitis is a multiorgan autoimmune inflammatory disease that has a heterogeneous clinical presentation. Our case report provides additional evidence supporting the association between granulomatosis with polyangiitis and myositis. In our patient with proximal muscle weakness and pain, a normal creatine kinase and lack of antibodies to muscular fiber units ruled out primary myositis. Read More

View Article and Full-Text PDF
January 2021

Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?

Respiration 2021 May 5:1-10. Epub 2021 May 5.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Interstitial lung disease (ILD) is a cause of substantial morbidity and mortality amongst autoimmune diseases, including myositis. Despite first-line therapy with immunosuppression, many inflammatory ILDs advance to a fibrotic stage. In such patients, progressive fibrosis may be amenable to treatment with antifibrotic medications, which were initially studied and approved for the treatment of idiopathic pulmonary fibrosis. Read More

View Article and Full-Text PDF

Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.

BMJ Case Rep 2021 May 4;14(5). Epub 2021 May 4.

The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Radiation recall (RR) is a chemotherapy-induced reaction that leads to inflammation and necrosis in previously irradiated tissue. Gemcitabine is a cytidine analogue that is often used in conjunction with nab-paclitaxel in the treatment of pancreatic cancer. Herein, we present a case of a 56-year-old woman with stage III pancreatic adenocarcinoma diagnosed with gemcitabine-induced RR when she presented with lower back pain and new rim-enhancing collections within the right and left paraspinal musculature 5 months after radiation therapy to the pancreas. Read More

View Article and Full-Text PDF

Clinical Results of Acetabular Fracture via the Pararectus versus Ilioinguinal Approach.

Orthop Surg 2021 May 4. Epub 2021 May 4.

Department of Orthopaedics, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

Objective: To compare the clinical efficacy of pararectus and ilioinguinal approach in the treatment of acetabular fractures.

Methods: A retrospective analysis of the clinical data of 60 patients with acetabular fractures treated by the pararectus approach or the ilioinguinal approach from January 2016 to January 2019 was performed to record all data by comparing the length of the surgical incision, the time to expose the fracture and the amount of blood loss during the operation. Patients were routinely followed up at 1, 6 and 12 months postoperatively. Read More

View Article and Full-Text PDF

Paraspinal Myosistis After Stereotactic Radiation Surgery.

Pract Radiat Oncol 2021 May-Jun;11(3):e348-e350

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

Myositis of the paraspinal muscles can be a clinically significant side effect of spinal radiation surgery. This report describes the typical clinical scenario, relevant radiologic findings, treatment, and management with the best available evidence. Read More

View Article and Full-Text PDF
January 2021

Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature.

J Clin Rheumatol 2021 Apr 28. Epub 2021 Apr 28.

From the Department of Autoimmune Diseases, Institut Clinic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Catalonia, Spain Department of Internal Medicine, Corporación Sanitaria Universitaria Parc Taulí, Sabadell, Barcelona, Catalonia Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias Department of Internal Medicine, Hospital Universitario Cruces, Barakaldo, Vizcaya Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza Department of Internal Medicine, Hospital Campus de la Salud, Complejo Universitario de Granada Department of Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada Department of Internal Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña Department of Internal Medicine, Hospital La Paz, Madrid Department of Internal Medicine, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Catalonia Department of Internal Medicine, Hospital de Cabueñes, Gijón, Asturias, Spain.

Objectives: To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis.

Methods: From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies. Read More

View Article and Full-Text PDF

Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction.

Se-Jin Lee

J Clin Invest 2021 May;131(9)

The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.

Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of skeletal muscle mass in 1997, there has been an extensive effort directed at understanding the cellular and physiological mechanisms underlying MSTN activity, with the long-term goal of developing strategies and agents capable of blocking MSTN signaling to treat patients with muscle loss. Considerable progress has been made in elucidating key components of this regulatory system, and in parallel with this effort has been the development of numerous biologics that have been tested in clinical trials for a wide range of indications, including muscular dystrophy, sporadic inclusion body myositis, spinal muscular atrophy, cachexia, muscle loss due to aging or following falls, obesity, and type 2 diabetes. Here, I review what is known about the MSTN regulatory system and the current state of efforts to target this pathway for clinical applications. Read More

View Article and Full-Text PDF

SARS-CoV-2 infection complicated with cold agglutinin disease and myositis.

Clin Case Rep 2021 Apr 16;9(4):2196-2199. Epub 2021 Mar 16.

Department of Medicine Section of hematology & oncology Goshen Center for Cancer Care Goshen IN USA.

This case emphasizes the importance of prompt comprehensive investigation of anemia and myositis in patients infected with SARS-CoV-2 and early recognition of uncommon complications that can be associated with SARS-CoV-2 infection. Read More

View Article and Full-Text PDF

Decreased Serum 25-(OH)-D Level Associated With Muscle Enzyme and Myositis Specific Autoantibodies in Patients With Idiopathic Inflammatory Myopathy.

Front Immunol 2021 15;12:642070. Epub 2021 Apr 15.

Department of Rheumatology, Shanxi Medical University Second Affiliated Hospital, Taiyuan, China.

Objectives: To determine whether there is serum vitamin D deficiency and the low levels of serum vitamin D are correlated with serological and immunological indexes in patients with idiopathic inflammatory myopathy (IIM).

Methods: A total of 63 newly diagnosed patients with IIM, and 55 age- and sex- matched healthy controls were enrolled. Serum levels of 25-(OH)-D were measured by enzyme-linked immunosorbent assay. Read More

View Article and Full-Text PDF

Tocilizumab as an alternative for corticosteroid-refractory orbital myositis.

J Neuroimmunol 2021 Apr 17;356:577573. Epub 2021 Apr 17.

Department of Neurology, Hospital Mútua Terrassa, Spain.

View Article and Full-Text PDF

Dexamethasone can be safely and effectively used for treatment of masticatory muscle myositis in dogs.

Top Companion Anim Med 2021 Apr 29:100538. Epub 2021 Apr 29.

Department of Neurology and Neurosurgery, Dick White Referrals, Six Mile Bottom, UK.

Dexamethasone is the glucocorticoid of choice in many human inflammatory and immune-mediated conditions, given its reported effectiveness and limited side effect profile. In veterinary medicine, the glucocorticoid of choice is prednisone, however the safety of longer-term use of dexamethasone has not previously been studied. The aim of this study was to evaluate the safety, effectiveness and side effects of dexamethasone use as the glucocorticoid treatment for masticatory muscle myositis in dogs - an immune-mediated inflammatory condition. Read More

View Article and Full-Text PDF